Revagenix is a precision-therapeutics company taking a first-principles approach to drug development for chronic disease. We start with the unmet need — the core biology and real world constraints that current therapies fail to address — and design each therapy for potency, delivery, and tolerability to meet those requirements.

This approach underpins our lead program, Rev-56 — precision engineered for inhaled delivery and designed to act where the disease takes hold, purpose-built with a novel MOA for non-CF bronchiectasis (NCFB) and the demands of its route of delivery. It also shapes the core capabilities we’re building as a company:

• Executional depth — a team with deep, hands-on experience advancing fit-for-market therapies from discovery through commercialization
• A scalable pipeline architecture — rooted in a repeatable, biology-driven design approach
• Partnership-driven innovation — embedded from the start, enabling us to leverage public- and private-sector support, including Novo Holdings, Tenmile, and the National Institutes of Health (NIH), to de-risk early-stage science and accelerate development